Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Texas Pacific Land Shares Test Key Support Ahead of Stock Split

Robert Sasse by Robert Sasse
December 3, 2025
in Analysis, Earnings, Energy & Oil
0
Texas Pacific Landration Stock
0
SHARES
8
VIEWS
Share on FacebookShare on Twitter

Shares of Texas Pacific Land Corporation find themselves under significant pressure, trading near annual lows as the market digests a disappointing quarterly report. This slump coincides with the finalization of plans for a significant stock split, leaving investors to ponder whether the current weakness presents a buying opportunity or signals further decline.

Quarterly Results Disappoint, Eroding Investor Confidence

The primary catalyst for the recent sell-off was the company’s third-quarter 2025 earnings release, which fell short of market projections. Earnings per share (EPS) came in at $5.27, missing the $5.69 estimate by 7.38%. Revenue also disappointed, totaling $203 million against expectations of $210 million, a shortfall of 3.3%. This earnings miss has directly contributed to the stock’s descent toward its yearly low.

Trading at a Critical Juncture

The stock’s current price of $864.70 places it alarmingly close to its 52-week low of $838.26. This level stands in stark contrast to its annual high of $1,610.96, highlighting the extent of the recent downward trend. The persistent selling activity reflects growing caution among shareholders.

A 1-for-3 Stock Split Finalized for December

Amid the price volatility, the company has confirmed the details of its previously announced 1-for-3 stock split. The record date for the split is set for December 12, 2025. Shareholders will receive the new, post-split shares on December 22, with trading on a split-adjusted basis commencing the following day, December 23. This corporate action will increase the number of outstanding shares without altering the firm’s overall market valuation.

Should investors sell immediately? Or is it worth buying Texas Pacific Landration?

Underlying Fundamentals Show Resilience

Despite the short-term headwinds, Texas Pacific Land’s foundational business metrics remain notably strong. The company boasts an exceptionally high gross profit margin of 94.13% and has consistently paid dividends for twelve consecutive years. Its balance sheet is robust, holding more cash than debt and featuring a current ratio of 10.86, indicating substantial liquidity.

Key Financial Metrics:
* Q3 2025 EPS: $5.27 (Estimate: $5.69)
* Q3 2025 Revenue: $203 million (Estimate: $210 million)
* Gross Profit Margin: 94.13%
* Dividend Track Record: 12 consecutive years
* Current Dividend Yield: 0.75%
* Balance Sheet: Net cash position
* Current Ratio: 10.86

Analyst Perspective: KeyBanc Identifies Value

Not all market observers are deterred by the recent performance. The analysis firm KeyBanc has initiated coverage on Texas Pacific Land with an “Overweight” rating and a price target of $1,050.00. This bullish stance suggests that some experts view the current price decline as a potential entry point, betting that the company’s solid fundamentals will ultimately be rewarded by the market. The central question for investors now is the timing of that potential recovery.

Ad

Texas Pacific Landration Stock: Buy or Sell?! New Texas Pacific Landration Analysis from February 7 delivers the answer:

The latest Texas Pacific Landration figures speak for themselves: Urgent action needed for Texas Pacific Landration investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Texas Pacific Landration: Buy or sell? Read more here...

Tags: Texas Pacific Landration
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Graftech Stock
Commodities

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Next Post
Block Stock

Block Stock: A Contrarian Buy Amidst the Sell-Off?

IonQ Stock

IonQ's Foray into Biotech: A Quantum Leap or a Costly Gamble?

MP Materials Stock

Institutional Investors Signal Confidence in MP Materials' Recovery

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com